In this three part series, we brought in experts to explain the process to bring a drug to market, such as discovering a potential drug in a lab, running clinical trials in humans, getting a drug approved by Health Canada to getting the drug covered by public and...
Canadian Arthritis Patient Alliance (CAPA) was offered an opportunity to provide feedback related to Health Canada’s Consultation: Handbook for healthcare professionals on biosimilar biologic drugs. CAPA has a Medical Advisory Committee (MAC), and all of our resources...
In July 2019, Health Canada began a 60-day consultation on the draft guidance: The Distinction Between Promotional and Non-promotional Messages and Activities for Health Products, formerly known as a policy entitled The Distinction Between Advertising and Other...
There are a number of biosimilar medications available to treat people with arthritis in Canada. A biosimilar is a biologic drug that is highly similar to a biologic drug that was already authorized for sale. Health Canada has recently updated its fact sheet on...
English 
Français du Canada